プレフィルドシリンジの世界市場:ガラス製/プラスチック製プレフィルドシリンジ

調査会社GMR Data社が発行したリサーチレポート(データ管理コード:GMRD5012)
◆英語タイトル:The Global Pre-Filled Syringe Market to 2024
◆発行会社/調査会社:GMR Data
◆商品コード:GMRD5012
◆発行日:2014年10月
◆調査対象地域:グローバル
◆産業分野:医療機器
◆ページ数:160
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserEUR1,799 ⇒換算¥239,267見積依頼/購入/質問フォーム
Departmental(部署内共有可)EUR3,599 ⇒換算¥478,667見積依頼/購入/質問フォーム
Site License(全社内共有可)EUR8,499 ⇒換算¥1,130,367見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
GMR Data社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[プレフィルドシリンジの世界市場:ガラス製/プラスチック製プレフィルドシリンジ]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

The Global Pre-filled Syringe Market 2014-2024 report analyses how this important sub-sector will continue to grow across the next decade. The report highlights key companies, geographies and products that we believe will deliver double digit growth across the next decade.

Buy this report today and acquire analysis of the state of the pre-filled syringes market in 2014 and a market forecastfor the period 2014-2024. Market forecasts are also provided for global pre-filled syringes for glass and plastics on the global level (value and volume) as well as for the geographic regions of key pre-filled syringe types (value and volume).

The advantages that will drive the growth of pre-filled syringes include ease of administration, improved safety, reduced risk of contamination, elimination of medication errors, low incidence of needlestick injuries, accurate dosing and reduction in medical expenditure due to reduced visits to healthcare facilities.

When compared to standard injectables, the pre-filled syringes market is still evolving, and its use is slowly increasing. Developed countries have shown a strong adoption rate for pre-filled syringes whereas developing & ROW countries have often been slow in adopting this technology. During the forecast period, however, the adoption rate will witness a healthy growth in emerging markets, and will witness a growth rate above that of developed geographies such as the US and in Europe.

The market is highly consolidated and is currently dominated by key global players such as Abbott Labs, Becton Dickinson, Baxter, Nipro Corporation, Schott, Gerresheimer, West Pharmaceutical, Ypsomed, Bespak and Unilife Corporation. Other companies such as Haselmeier; Weigao Group, Nuova Ompi (Stevanato Group), Owen Mumford and Vetter Pharma are likely to foster innovation in the coming years.

*** レポート目次(コンテンツ)***

1- Executive Summary
1.1 Global Pre-filled Syringes Market Review
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Drivers & Restraints of the Global Pre-Filled Syringe Market 2014-2024
1.4.1 Drivers
1.4.1.1 Growth of the Injectable Drugs Market
1.4.1.2 Success & Growth of Biologics
1.4.1.3 Increased Global Vaccination
1.4.1.4 Increased Drug Self-Administration
1.4.1.5 Technological Advances in the Manufacture of PFS
1.4.1.6 Advances in PFS Technology
1.4.2 Restraints
1.4.2.1 Increased Manufacturing / Distribution Costs
1.4.2.2 Alternative Drug Delivery Methods
1.4.2.3 Controlled Release

2 -Introduction to the Pre Filled Syringe Market
2.1 Introduction to Pre-filled Syringes
2.1.1 What are Pre-Filled Syringes
2.1.2 Market Overview of Pre-filled Syringes
2.1.3 An Increasingly Accessable Sector
2.1.4 Key Advances in the PFS Industry
2.2 Components of Pre-filled Syringes
2.3 Types of Pre-filled Syringes
2.3.1 Glass Syringes
2.3.2 Plastic Syringes
2.4 Classification of Pre-filled Syringes
2.4.1 Single-chamber and Dual-Chamber
2.4.2 Type of needle
2.5 Injection delivery devices
2.5.1 Pen Injectors
2.5.2 Insulin pens
2.5.3 Auto-Injectors
2.5.4 Needle-Free Injectors
2.5.5 Drugs available in Pre-filled Syringes
2.6 Concerns over needle stick Injuries

3 -Global Pre-Filled Syringe; Market Revenue and Volume Forecasts to 2024
3.1 Global Market Overview
3.1.1 Global Pre-filled Syringes Market Revenue, 2013-2024
3.1.2 Global Pre-filled Syringes Market Volume, 2013-2024
3.2 Glass Pre-filled syringes
3.2.1 Global Glass Pre-filled Syringes Market Revenue, 2013-2024
3.2.2 Global glass Pre-filled Syringes Market size, 2013 – 2024
3.3 Plastic Pre-filled syringes
3.3.1 Global Plastic Pre-filled Syringes Market Revenue, 2013 – 2024
3.3.2 Global Plastic Pre-filled Syringes Market size, 2013 – 2024

4 – Key Geographies in the Global Pre-Filled Syringe Market 2014-2024
4.1 Global Market Overview
4.2 The North America PFS Market 2013-2024
4.2.1 Key drivers in the North American PFS market
4.2.1.1 Increase in Cancer Treatment
4.2.1.2 Spending on multiple sclerosis (MS)
4.2.1.3 Increase in Diabetes Prevalence
4.2.1.4 Healthcare Expenditure
4.2.1.5 Spend on Vaccination
4.2.1.6 Regulatory Environment for Pre-Filled Syringes
4.3 The Europe PFS Market 2013-2024
4.3.1 Key factors that will drive the PFS market in Europe
4.3.1.1 Favourable reimbursement policies
4.3.1.2 Increased Spend on Healthcare
4.3.1.3 Increase in Europe Wide Diabetic Population
4.3.1.4 Strong contribution to the Biosimilar Market
4.3.1.5 Increase in Cancer Treatment
4.3.1.6 Regulatory Environment
4.4 The Asia Pacific PFS Market 2013-2024
4.4.1 Key drivers of the APAC PFS Market
4.4.1.1 Emerging Middle Classes
4.4.1.2 APAC Diabetes Market
4.4.1.2.1 China Diabetic Market
4.4.1.2.2 India Diabetic Market
4.4.1.2.3 Japanese Diabetic Market
4.4.1.3 Increase in Vaccination demand
4.4.1.3.1 Japanese Vaccination Market
4.4.1.3.2 India Vaccination Market
4.4.1.3.3 China Vaccination Market
4.4.1.4 Growing Cancer Drugs Market Across APAC
4.4.1.4.1 Japanese Cancer Drugs Market
4.4.1.5 Increased Biotechnology Across APAC
4.4.1.5.1 China Biotechnology
4.4.1.5.2 India Biotechnology
4.4.1.5.3 Japan Biotechnology
4.5 The Rest of the World PFS Market 2013-2024
4.5.1 Key drivers of the ROW PFS market
4.5.1.1 Increased demand for Vaccination
4.5.1.1.1 Russian demand for Vaccination
4.5.1.1.2 Brazil Vaccination Landscape
4.5.1.2 Increasing prevalence of Diabetes
4.5.1.2.1 The Brazilian Diabetes Sector
4.5.1.2.2 The Russia Diabetes Sector
4.5.1.3 Increased Healthcare Spending

5 -Leading Therapeutic Segments for Pre-Filled Syringes 2013-2024
5.1 Biologics
5.1.1 Next Generation Biologics
5.1.2 Biologics Pipeline
5.1.3 Key Biologics Exiting Patent
5.2 Biosimilars
5.2.1 Monoclonal Antibodies
5.2.2 Insulin
5.2.3 Erythropoietin
5.2.4 Interferons
5.2.5 G-CSF
5.2.6 Human Growth Hormones
5.3 Vaccines
5.4 Antirheumatics
5.5 Anticoagulants
5.6 Diabetes
5.7 Multiple Sclerosis (MS)

6 – SWOT Analysis of the Global Pre-Filled Syringes Market 2014-2024
6.1 Strengths
6.1.1 Ease of use
6.1.2 Accurate Dosage
6.1.3 Reduced Incidence of Needlestick Injuries
6.1.4 Economic advantages
6.2 Weaknesses
6.2.1 Product stability/compatibility issue
6.2.2 Air bubbles during filling
6.2.3 Device Operation issues
6.2.4 Extractables and Leachables contamination
6.3 Opportunities
6.3.1 Increase in the number of self-injecting patients
6.3.2 Growth of Biologics & Biosimilars
6.3.3 Geographic expansion
6.3.4 Vaccination Programmes
6.3.5 Ageing population
6.4 Threats
6.4.1 Alternative Drug Delivery Platforms
6.4.2 Manufacturing complexities
6.4.3 Manufacturer Recalls
6.4.4 Stringent Regulatory Environment

7 -Company Profiles
7.1. Abbott Labs
7.2: Baxter International
7.3: Becton Dickinson
7.4: Schott AG
7.5. Nipro Corporation
7.6: Gerresheimer AG
7.7. West Pharmaceutical Services
7.8. Ypsomed Holding AG
7.9: Bespak
7.10: Unilife Corporation
7.11: Haselmeier
7.13: Weigao Group
7.14: Owen Mumford

8 -Expert Opinion
8.1 Schott Kaisa
8.2 West Pharmaceuticals
8.3 Fresenius Kabi

Tables

Table 1.4: Drivers & Restraints of the Global Pre-Filled Syringe Market 2014-2024
Table 1.4.2.2: Total Diabetics & Treatment Statistics US, 2013 (million people)
Table 2.2.1: Components of PFS
Table 2.2.2: Key components and description of PFS
Table 2.4.1.1: Advantages of dual-chamber system
Table 2.5.1: Classification of injectors depending upon of the type Use and User
Table 2.5.2.1: Different brands of Insulin available in the market
Table 2.5.3.1: Benefits of Auto-injector
Table 2.5.4.1: Advantages of needle-free
Table 2.5.6.1: Categories of drugs where PFS are used:
Table 3.1.1.2: Breakdown of Pre-filled Syringes market by region, 2013 ($ bn)
Table 3.1.2.1: Pre-filled Syringe Market; Total Revenue, Total Units, Glass Revenue & Plastic Revenue 2013-2024 ($/bn, %)
Table 3.1.2.2: Total Revenue, Total Units, Glass & Plastic 2013, 2014, 2019 & 2024 ($/bn, %)
Table 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %)
Table 4.1.2: Forecast of Regional CAGR 2014-2024 (%)
Table 4.1.3; Regional PFS Market Share Breakdown (%)
Table 4.1.4: Forecast of Regional Market Share 2014, 2019 & 2024 ($/bn & %)
Table 4.1.5: Forecast of Global PFS Revenue & Total Units Shipped 2013-2024 ($/bn & billion units)
Table 4.1.6: Regional PFS Unit Sales (billion)
Table 4.2.1: The North America PFS Market Forecast 2013-2024 ($/bn & AGR %)
Table 4.2.2: The North America PFS Unit Forecast 2013-2024 (billion)
Table 4.2.3: Estimated Incidence, Mortality, and Prevalence of Cancer Worldwide and US - 2012
Table 4.2.4: Total Diabetics & Treatment Statistics, US, 2013 (million people)
4.2.5: Diabetes population, prevalence and healthcare expenditure in the US and Canada (2013)
Table 4.2.6: US Healthcare Spending Per Capita 2000-2013 ($, %)
Table 4.3.1: The Europe PFS Market 2013-2024 ($/bn)
Table 4.3.2: Forecast of European PFS Unit Sales 2013-2024 (Billion Units)
Table 4.3.3 PFS Revenue, by Geography, Europe 2013 ($/ bn / %)
Table 4.3.4: EU5 GDP & Healthcare Spending, 2012 ($/bn)
Table 4.3.5: Diabetes population, prevalence and healthcare expenditure in Europe – 2013 ($)
Table 4.3.6: Estimated Incidence and Mortality rate of Cancer in Europe - 2013
Table 4.4.1: Asia-Pacific & Global PFS Market ($/bn & AGR)
Table 4.4.2: Forecast of Asia-Pacific PFS Unit Sales 2013-2024 (Billion Units)
Table 4.4.3: GDP Growth, India & China 1990-2010 ($/bn, %)
Table 4.4.4: Number of Population with Diabetes in China 2008-2030
Table 4.4.5: China Diabetes Annual Figures, 2013
Table 4.4.6: India Diabetes Annual Figures, 2013
Table 4.4.7: Japan Diabetes Annual Figures, 2013
Table 4.4.8: Incidence, Mortality, and Prevalence of Cancer Worldwide, China, India & Japan 2012
Table 4.4.9: China Pharmaceutical Market for Oncology, 2008 – 2013
Table 4.4.10: APAC Biologics & Biosimilars Market Size 2013 ($/bn)
Table 4.4.11: Key Biosimilars Approved in India 2014
Table 4.4.12: PMDA Approved Biosimilars in Japan 2014
Table 4.5.1: The Rest of the World PFS Market 2013-2024 ($/bn, %)
Table 4.5.2: Forecast of ROW PFS Unit Sales 2013-2024 (Billion Units)
Table 4.5.3; Russian Vaccines Profile 2014
Table 4.5.4: Brazilian Vaccines Profile 2014
Table 4.5.5: Diabetes population, prevalence and healthcare expenditure in Brazil, 2013
Table 4.5.6: Diabetes population, prevalence and healthcare expenditure in Russian, 2013
Table 4.5.7: GDP Growth Brazil & Russia 2000-2010 ($/bn)
Table 4.5.8: Russia & Brazil GDP & Healthcare Spend 2000, 2005 & 2010 ($/bn)
Table 5.1.1: Global Biologics Market Size by Region, 2013 ($/bn)
Table 5.1.2: Biologic medicines under development-by therapeutic category 2014
Table 5.1.3: Biologic medicines under development-by product category 2014
Table 5.1.4: Expiry dates for major patents on best-selling biological products 2011-2024
Table 5.1.5: Key products potential targeted by biosimilar developers post patent expirations
Table 5.2.1: Global Biosimilars Market Size by Region, 2013 ($/bn)
Table 5.2.2: Key Drivers of the Global Biosimilar Market
Table 5.2.3: Key Restraints in the Global Biosimilar Market 2014
Table 5.2.4: Biologics, which lose patent and the opportunity for Biosimilars 2013 ($/bn)
Table 5.2.5: Biologics under different phases of trials
Table 5.3.1: Vaccine manufacturers’ classification for supply
Table 5.3.2: Top 10 best-selling vaccine, manufacturer and application 2013
Table 5.5.3: Global Anticoagulants market by region, 2013 ($/bn, %)
Table 5.6.1: Top 10 selling diabetes drugs, 2013
Table 6.1: SWOT Analysis of the Global Pre-filled Syringes Market 2014-2024
Table 6.3.1: Diabetes in the US, Diagnosed, Undiagnosed and New Cases 2012
Table 6.3.2: BRIC Population, Healthcare Expenditure per Capita 2006 / 2012 ($/p/a)
Table 7.1.1: Abbott Labs Key PFS/BGMS Products, 2014
Table 7.2.1: Baxter International Key PFS Products, 2014
Table 7.3.1: Key Becton Dickinson PFS / IV Products, 2014
Table 7.4.1: Schott Key PFS/Needle Products, 2014
Table 7.5.1: Nipro Corporation Key PFS / Related Products, 2014
Table 7.6.1: Gerresheimer Key PFS / Syringe Products, 2014
Table 7.7.1: West Pharmaceutical Key Products, 2014
Table 7.8.1: Ypsomed Key PFS/Injection Products, 2014
Table 7.9.1: Bespak Key PFS / Syringe Products, 2014
Table 8.10.1: Unilife Corporation Key PFS/Injection Products, 2014
Table 7.11.1: Haselmeier Key PFS / Injection Products 2014
Table 7.13.1: Weigao Group Key PFS / Syringe Products, 2014
Table 7.14.1: Owen Mumford Key PFS / Syringe Products, 2014

List of Figures

Figure 2.6.1: Breakdown of Risk of Needlestick Injury 2014
Figure 3.1.1.1: Forecast of the Global Pre-filled Syringes Market, 2013-2024 ($/bn)
Figure 3.1.1.2: Breakdown of Pre-filled Syringes market by region, 2013 ($/bn)
Figure 3.1.2.1: Forecast of the Global Pre-filled Syringes Market, 2013-2024 (bn units)
Figure 3.2.1.1: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 ($/bn)
Figure 3.2.2.1: Forecast of the Global Glass Pre-filled Syringes Market, 2013-2024 (bn units)
Figure 3.3.1.1: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 ($/bn)
Figure 3.3.2.1: Forecast of the Global Plastic Pre-filled Syringes Market, 2013-2024 (bn units)
Figure 4.1.1: Global PFS Market Revenue Forecast 2013-2024 ($/bn, %)
Figure 4.1.2 Percentage Share of the Global PFS Market, 2014 (%)
Figure 4.1.3 Percentage Share of the Global PFS Market, 2019 (%)
Figure 4.1.4 Percentage Share of the Global PFS Market, 2024 (%)
Figure 4.2.1 PFS Unit sales, US, (billions) 2013-2024
Figure 4.2.2 US Healthcare Spending Per Capita 2000-2013 ($)
Figure 4.3.1 PFS Unit sales, Europe, (billions) 2013-2024
Figure 4.3.2 PFS Market Revenue, by Geography, Europe, 2013 (%)
Figure 4.3.3: EU5 GDP & Healthcare Spending, 2012 ($/bn)
Figure 4.3.4 China Per Capita Disposable Income 2005-2013 ($)
Figure 4.4.1 PFS Unit sales, ROW, (billions) 2013-2024
Figure 4.4.2 Russia & Brazil Healthcare Spend 2000, 2005 & 2010 ($/bn)
Figure 5.1.1: Global Biologics Market Forecast, 2013-2024 ($/bn)
Figure 5.1.2: Global Biologics Market Size by Region, 2013 ($/bn)
Figure 5.2.1: Global Biosimilar Market Forecast, 2013-2024 ($/bn)
Figure 5.2.2: Global Biosimilar Market Size by Region, 2013 ($/bn)
Figure 5.3.1: Global Vaccine Market Forecast, 2013-2024 ($/bn)
Figure 5.4.1: Global Anti-rheumatics Market Forecast, 2013-2024 ($/bn)
Figure 5.4.2: Market Share of Key Players in Anti-rheumatics Market, 2013 (%)
Figure 5.4.3: Market Share of Key Brands in Anti-rheumatics Market, 2013 (%)
Figure 5.5.1: Global Anticoagulants Market Forecast, 2013-2024 ($/bn)
Figure 5.5.2: Global Anticoagulants Market, by region, 2013 (%)
Figure 5.6.1: Global Anti-diabetic Drugs Market Forecast, 2013-2024 ($/bn)
Figure 5.7.1: Breakdown of Multiple Sclerosis Market, by Region; 2013, ($/bn)
Figure 5.7.2: Forecast of the Global Multiple Sclerosis Market, 2013-2024 ($/bn)
Figure 5.7.3: Top 5 MS Brands, Market Share, 2013
Figure 8.1.1: Abbotts Regional Sales Breakdown, 2013
Figure 8.2.1: Baxter Regional Revenue Breakdown 2013
Figure 8.4.1: Schott’s Net Sales, by Region, 2013
Figure 8.5.1: Nipro Regional Net Sale Breakdown, 2013-2014
Figure 8.6.1: Gerresheimer AG Regional Net Sales, 2013-14
Figure 8.7.1: West Pharmaceutical Regional Net Sales, 2013-14

*** 掲載企業 ***

Abbott Labs
AbbVie
Aesica
AesRX LLC (Part of Baxter International)
Amgen
Antares Pharma Inc.
Bausch
Baxter
Bayer
Becton Dickinson
Berlin-Chemie
Biocon
Biogen Idec
Biogen Inc.
Biosensors International Group
BMS
Boehringer Ingelheim
Bracco Diagnostics Inc.
Carl Zeiss Foundation
Cato Software Solutions (Part of BD)
CB Medical Holdings Limited
Cell Science & Technology Institute (Part of Nipro Corporation)
Celltrion
Coherus
Contract Development and Manufacturing Organisation (CDMO)
Daiichi Sanyo
Developing Countries Vaccine Manufacturers Network (DCVMN)
Dong-A Pharmaceutical
Egis
Eli Lilly
European Medicines Agency (EMA)
European Union (EU)
Ferring Pharmaceuticals
Food and Drug Administration (FDA)
Gambro AB (Part of Baxter International)
Genentech
GeneScience Pharmaceuticals
Genzyme
Gerresheimer
GlaxoSmithKline
Globe Medical Tech
Haselmeier
Hospira
Hyaluron Contract manufacturing
International Federation of Pharmaceutical Manufacturers and Association (IFPMA)
Itochu
Johnson & Johnson
Kapoor Glass
Medical Glass (Now a part of Stevanato Group)
Medpro safety Products
Merck & Co.
Merck Serono
Nipro Corporation
Novartis
Novo Nordisk
Nuova Ompi (Stevanato Group)
Ompi of America (Now a part of Stevanato Group)
Owen Mumford Ltd.
Pfizer Australia Pty
Pfizer Inc.
Pharmstandard
Rhone-Poulenc-Rorer
Roche
Sandoz International
Sanofi-Aventis
Schott AG
Schott-Kaisha India
SHL Group
Stevanato group (Nuova Ompi)
Strobel
Takeda
Terumo Europe
Terumo Medical Corp.
Teva Neuroscience
Teva Pharmaceuticals
UB Pharma
UCB
Unilife Corporation
Vetter Pharma
Weigao Group
West Pharmaceuticals Services
Wilco AG
Ypsomed

*** レポートのキーワード ***

プレフィルドシリンジ、注射器、薬剤、ガラス製プレフィルドシリンジ、プラスチック製プレフィルドシリンジ

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMRD5012 )"プレフィルドシリンジの世界市場:ガラス製/プラスチック製プレフィルドシリンジ" (英文:The Global Pre-Filled Syringe Market to 2024)はGMR Data社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。